LiquidBiopsy® Tunable Assay Architecture Supports User-Defined Protocols

The LiquidBiopsy® cell enrichment platform is capable of processing a wide variety of sample inputs and supports a full suite of readout protocols for maximum analytical flexibility. The system has an open and tunable architecture that can readily be adapted to additional capture biomarkers, affinity reagents, and user defined research assays.

The flexible design of the LiquidBiopsy® platform supports a variety of research areas, including:

  • Oncology
  • Stem Cell Research
  • Immunology
  • Infectious Disease
  • Endothelial Cells
  • Fetal Cells / Noninvasive Prenatal Testing (NiPT)
  • Peptide/Aptamer Libraries

A Competitive Differentiator for Cancer R&D Programs

With the ability to deliver high-purity, high-volume rare cell sample populations that can be easily analyzed off-platform, the LiquidBiopsy system maximizes downstream process utility and makes real-time molecular data analysis a reality.  The platform's automated rare cell workflow makes it a cost-effective and easy choice for a wide array of personalized cancer research projects, especially those focused on DNA and RNA sequencing from blood.

The platform leverages enhanced immunomagnetic capture within a patented microfluidic flow chip to recover rare cells from whole blood. The performance profile of the LiquidBiopsy platform immediately enables advanced molecular analysis, and serves as a front-end for NGS and PCR expression analysis, as well as for FISH and IHC and enumeration/scanning workflows. Uniquely, LiquidBiopsy-derived cell populations can be removed from the chip and directly sequenced without a need for whole genome amplification.
 

Partnering with Industry Leaders and Major Research Centers

Cynvenio’s LiquidBiopsy technology has been validated through partnerships with major cancer centers such as USC’s Norris Cancer Center (Los Angeles, CA), Memorial Sloan-Kettering (New York, NY), and Jefferson University Kimmel Cancer Center (Philadelphia, PA).  

The flexible design of the LiquidBiopsy platform supports a variety of research areas, including:

  • Oncology
  • Stem Cell Research
  • Immunology
  • Infectious Disease
  • Endothelial Cells
  • Fetal Cells
  • Peptide/Aptamer Libraries
/*This is to open gallery links in new window*/